Considering that A18 inhibited NF-kB signaling pathway and cytokine production in infected cells in vitro, and its known immunomodulatory activity in different in vivo models [15,16], we propose that A18 may show a protective effect against pulmonary RSV infection by reducing viral infection, and by affecting the NF-κB signaling and cytokine response as well. This evidence concerns the gene NFKB1 and viral infectious disease.